CHARMed - An update on the Combination HIV Antiretroviral Rectal Microbicide program
Where:
Teleconference
When: Sep 14, 2010 starts at 10:00 am
Join Ian McGowan, Principal Investigator, to
learn about the status of CHARM - the
Combination HIV Antitretrovial Rectal
Microbicide Program - a 5-YEAR, $11 million
project funded by the NIH.. The purpose of
CHARM is to develop rectal-specific
anitretroviral microbicides. Candidates include
tenofovir, UC781, and a combination of
tenofovir and UC781. Learn more in Section 2 of
IRMA's report "From
Promise to Product: Advancing Rectal
Microbicide Research and Advocacy."